Best Cardiac and Vascular Disorders Companies in New York, United States
The 68 best Cardiac and Vascular Disorders companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everest Medicines.
Ranked: Best Cardiac and Vascular Disorders companies in New York
| # | Company | Disclosed funding | Last round | Employees | Stage | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Everest Medicines Developer of drugs for the treatment of cancer | $593M | 72 mo ago | 395 | Public | Kerry Blanchard CEO | Node.jsSvelteKitSvelte+5 | — | 3 partnerships |
| 2 | Caladrius Biosciences Developer of cell therapy based drugs for coronary microvascular dysfunction, diabetes, cancer and limbic… | $128M | 65 mo ago | 53 | Public | — | — | — | — |
| 3 | Applied Therapeutics Developer of drugs for the treatment of metabolic and cardiovascular diseases | $65M | 27 mo ago | 25 | Acquired | — | WordPressDrupalMySQL+34 | — | — |
| 4 | Huinno Developer of AI and cloud-based device for cardiac health monitoring and activity tracking | $48M | 53 mo ago | 91 | Series C | Yeongjoon Gil Co-Founder & CEO | — | — | 2 partnerships |
| 5 | Peerbridge Health Developer of ambulatory ECG system with AI-enabled cardiac diagnostics 42Innovation top 23%Funding top 27%Product top 30%Moat top 39% All 7 signals ▾Innovationtop 23% Fundingtop 27% Producttop 30% Moattop 39% Techtop 48% Globalbottom 37% Marketbottom 19% Innovation: 4 product lines · Deep-tech classification: Tech Hardware Funding: Raised $46.1M across 14 rounds · 14 rounds over 11 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $46M | 13 mo ago | 3 | Series B | — | HubSpot CMS Hubcore-jsOWL Carousel+15 | — | 1 launch · 1 expansion |
| 6 | ARMGO Pharma Developer of small molecule therapeutics to treat debilitating cardiac and vascular disorders | $36M | 15 mo ago | 9 | Series B | — | — | — | — |
| 7 | Myocardial Solutions Provider of MRI-based diagnostic software for cardiac disease | $31M | 35 mo ago | 20 20 → 32 (+60%) | Series B | Nael Osman Founder | — | 22 patents Cardiac MRI strain quantification for rapid heart function assessment and monitoring | — |
| 8 | CHF Solutions Ultrafiltration devices to treat fluid overload | $23M | 257 mo ago | 50 | Acqui-Hired | — | — | 84 patents Neonatal/paediatric extracorporeal blood filtration and cardiac assist device technologies | — |
| 9 | Feelmore Labs Online platform offering diverse products, including electronics, fashion, and home goods | $20M | 78 mo ago | 7 | Series A | Francois Kress CEO | — | — | — |
| 10 | Cibiem Medical device for Carotid Body Modulation. | $10M | 164 mo ago | 3 | Series A | — | — | 57 patents Patents concentrated in health & consumer products | — |
| 11 | Axon Therapies Developer of ablation device for heart failure treatment | $7M | 8 mo ago | 18 | Series A | Mark Gelfand Co-Founder | — | 63 patents Endovascular splanchnic nerve ablation devices for cardiovascular and metabolic therapy | — |
| 12 | Scienture Developer of therapeutics for CNS, oncology, and cardiovascular disease | $6M | 11 mo ago | 6 | Public | — | WordPressMySQLPHP+13 | 24 patents Sustained‑release liquid and injectable drug formulations for cardiovascular and analgesic therapies | 2 launchs |
| 13 | ImaCor Hemodynamic Ultrasound solutions for critical care, improving patient outcomes | $5M | 208 mo ago | 24 | Series A | Peter Pellerito President and CEO | — | 68 patents Advanced ultrasound hemodynamic monitoring and transesophageal imaging probe technologies. | — |
| 14 | ImaCor Critical care solution that enables clinicians to viauslize heart in the ICU in real time | $5M | 208 mo ago | — | Deadpooled | Peter Pellerito President & CEO | — | 68 patents Patents concentrated in health & consumer products | — |
| 15 | Hybernia Medical Developer of solutions for acute ischemic stroke treatment | $5M | 75 mo ago | 2 | Series A | — | — | — | — |
| 16 | Proteonomix Developing therapeutics based upon the use of human stem cells and their derivatives to treat cardiac… | $4M | 171 mo ago | 2 | Deadpooled | Michael Cohen CEO & President | — | 8 patents Stem cell mobilization, isolation, and culture technologies for regenerative medicine applications. | — |
| 17 | Vicora Developer of a thrombectomy system utilizing integrated distal tip vibration | $3M | 16 mo ago | — | Series A | Shawn Patterson CEO | — | 10 patents Electroactive polymer actuators for minimally invasive medical devices, e.g., thrombectomy tools. | — |
| 18 | Cloud Provider of cloud-based remote cardiology vital signs monitoring devices and platforms 67Growth top 21%Innovation top 22%Patents top 23%Moat top 32% All 11 signals ▾Growthtop 21% Innovationtop 22% Patentstop 23% Moattop 32% Fundingtop 35% Fin. healthtop 38% Producttop 39% Techbottom 48% Globalbottom 46% Newsbottom 40% Marketbottom 37% Growth: Revenue +701% YoY · Fresh capital in last 24 mo Innovation: 85 patents (top 21% of patent-holders) · 23 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $3M | 2 mo ago | 55 | Public | — | Apple iCloud MailMicrosoft 365Zoho+26 | 85 patents Cloud-based health monitoring, telemedicine data transmission, and AR biomedical analytics | — |
| 19 | Cornovus Cardioprotective agents for heart failure treatment | $2M | 29 mo ago | — | Deadpooled | Bruce T Liang Founder | — | — | — |
| 20 | Nanowear Wearable garment based on nanosensor technology for medical monitoring | $2M | 104 mo ago | 22 | Seed | — | Cart FunctionalitySquarespace CommerceSquarespace+14 | 34 patents Integrated nanosensor textiles for continuous cardiac, pulmonary, neurological and wound monitoring | — |
| 21 | VPGMedical Digital health service providing video-based, contactless health monitoring solutions | $1M | 78 mo ago | 8 | Seed | Jean-Philippe Couderc Co-founder and CEO | — | — | — |
| 22 | Global Instrumentation Developer of ECG recorder and analysis system | $1M | 95 mo ago | 15 | Funding Raised | Jim DeMaso CEO & President | — | — | — |
| 23 | Auxilius Pharma Provider of FDA-approved medications for cardiovascular | $1M | 36 mo ago | 6 | Seed | — | — | — | — |
| 24 | RyCarma Therapeutics Developer of small molecule therapeutics for cardiovascular and skeletal muscle diseases | $1M | 57 mo ago | — | Funding Raised | Andrew Marks Founder | — | — | — |
| 25 | VentriNova Developer of viral vector-based gene therapy for regenerating heart muscle cells | $1M | 201 mo ago | — | Deadpooled | Hina Chaudhry Founder | — | — | — |
| 26 | SmartEKG Provider of smartphone-based heart monitoring device for patients and providers | $500K | 143 mo ago | — | Deadpooled | Benji Strauss Founder & CEO | — | — | — |
| 27 | CardioMag Imaging Non invasive cardiac diagnostic device | $500K | 259 mo ago | — | Early Stage | Carl Rosner Founder | — | 17 patents AI-driven analysis of magnetocardiogram signals for cardiac ischemia detection | — |
| 28 | Angiograft Regenerative medicine company providing off-the-shelf vascular grafts for cardiovascular disease | $446K | 105 mo ago | — | Funding Raised | Sindhu Row Co-Founder & COO | — | — | — |
| 29 | Anova Biomedical Developer of next-generation biodegradable vascular prosthetics | $275K | 21 mo ago | — | Funding Raised | Yadong Wang Co-Founder | — | — | — |
| 30 | NangioTx Developer of tissue-regenerative peptides for the treatment of peripheral arterial disease | $225K | 75 mo ago | 2 | Seed | Vivek Kumar Co-Founder & CEO | — | — | — |
Top 12 Cardiac and Vascular Disorders companies in New York
#1
Public · Brooklyn, New York · founded 2014 · 55 employees$3.1Mraised▾
Provider of cloud-based remote cardiology vital signs monitoring devices and platforms. Its product is a virtual medical device that records a pulse wave signal from the wrist uploads it to the cloud and derives the major vital signs. It lets physicians monitor the signs of patients remotely to manage their conditions and progress in treatment and medication.
- Mar 2026Post IPO$578.1K
- Apr 2024Post IPO$2.1M
- Dec 2023Post IPO$1.9M
- Jul 2023Post IPO$2.7M
#2
Series B · New York City, New York · founded 2012 · 3 employees$46.1Mraised▾
Developer of ambulatory ECG system with AI-enabled cardiac diagnostics. The company provides a platform that captures high-fidelity signals, transforming complex data into decision-ready insights. It offers an FDA-cleared wearable device that integrates into existing clinical workflows. The system is designed to enable earlier detection and proactive management of cardiac conditions.
- May 2025Series B$7.2M
- Jun 2024Series B$13.7M
- Feb 2023Series B$5M
- Oct 2022Series B$725K
#3
Series B · New York City, New York · founded 2004 · 9 employees$36Mraised▾
Developer of small molecule therapeutics to treat debilitating cardiac and vascular disorders. The company's proprietary drug, Rycals, is a new class of oral agents that repair calcium leak through the ryanodine receptor calcium-release channel (RyR), which is located on the sarcoplasmic/endoplasmic reticulum of the cell.
- Mar 2025Grant (prize money)$1M
- Dec 2021Series B$35M
- Aug 2011Seed$1M
#4
Series A · New York City, New York · founded 2014 · 18 employees$7Mraised▾
Developer of ablation device for heart failure treatment
- Sep 2025Series A$32M
- Aug 2022Series A$5M
- Apr 2016Series A$2M
#5
Public · Hauppauge, New York · founded 2019 · 6 employees$6Mraised▾
Developer of therapeutics for CNS, oncology, and cardiovascular disease. The company's lead candidates include SCN-101, SCN-104, and SCN-105 are used to treat CNS disease, SCN-102 is for oncology, and SCN-103 and SCN-106 are used to treat cardiovascular disease. The company is also developing therapeutics including SCN- 07 for pain, SCN-108 for endocrinology, and SCN-109 for anti-infective diseases.
- Jul 2025Post IPO$1.7M
- Nov 2024Post IPO$3.3M
- Dec 2020Post IPO$6M
#6
Acquired · New York City, New York · founded 2015 · 25 employees$65.2Mraised▾
Developer of drugs for the treatment of metabolic and cardiovascular diseases. The company's product line include AT-007 (govorestat), is a central nervous system-penetrant aldose reductase inhibitor designed for treating rare metabolic disorders such as galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase (CMT-SORD) deficiency, and PMM2-CDG. The company also develops AT-001 (caficrestat), for diabetic cardiomyopathy and diabetic peripheral neuropathy, along with preclinical efforts like AT-003 for diabetic retinopathy.
- Feb 2024Post IPO$100M
- May 2023Post IPO$30M
- Nov 2019Post IPO$20M
- Feb 2019Series B$25M
#7
Series A · Buffalo, New York · founded 2021$3.4Mraised▾
Developer of a thrombectomy system utilizing integrated distal tip vibration. The system is designed for clot removal without capital equipment. It focuses on trackability to improve clot removal efficiency. The device is currently in the research and development phase and not available for sale.
- Jan 2025Series A$3.4M
#8
Public · New York City, New York · founded 2017 · 395 employees$593Mraised▾
Developer of drugs for the treatment of cancer. The company has a portfolio of eight promising drug candidates for oncology, immunology, cardio-renal disease, and infectious disease. The company is developing kinase inhibitors that include FGF401 which is a fibroblast growth factor receptor 4 kinase inhibitor used to treat cancer.
- Jun 2020Series C$260M
- Mar 2020Series C$50M
- 2018Series A$3M
#9
Series B · Morrisonville, New York · founded 2002 · 20 employees$30.9Mraised▾
Provider of MRI-based diagnostic software for cardiac disease. It has developed three products SENC calculates cardiac strain in a single heartbeat, eliminating the need to hold the breath, HARP is an FDA-cleared software that automatically analyzes tagged MRI images and measures cardiac function and VIRTUE provides a suite of tools to view and analyze cardiac images.
- Jun 2023Series B$2.7M
- Mar 2021Series B$11.2M
- Mar 2019Series A$7M
- Jul 2017Series A$5M
#10
Public · New York City, New York · founded 1980 · 53 employees$128.3Mraised▾
Developer of cell therapy-based drugs for coronary microvascular dysfunction, diabetes, cancer, and limbic ischemia. The company has developed 3 immune-modulating technologies namely - T Regulatory Cell Technology (which infuses polyclonal antibodies to restore the immune balance that is distorted in most cases of autologous and allergic diseases), Tumor Cell / Dendritic Cell Technology (which involves the use of Cancer-Initiating Cells and dendritic cells to mount an immune response) and a CD34 Cell Technology (that involves the transfer of CD34 cells in the bone marrow and peripheral blood for ischemic repair). Its pipeline has cell therapies for type 1 diabetes based on T-regulatory (Treg) cell-based therapy and limbic ischemia (based on CD34 cell technology). The company partners with others to co-develop therapies based on its technologies and also has a subsidiary called PCT, a cell therapy CDMO. Caladrius, in partnership with Invetech, is also developing a closed processing system to increase the level of automation in cell manufacturing processes.
- Jan 2021Post IPO$25M
- Jan 2017Post IPO$6M
- Sep 2016Post IPO$12.6M
- Mar 2016Post IPO$1M
#11
Series C · New York City, New York · founded 2015 · 91 employees$47.6Mraised▾
Developer of AI and cloud-based device for cardiac health monitoring and activity tracking. It provides users with a company that offers electrocardiogram solution that attached to the human body integrated with AI and electrodes for arrhythmia detection.
- Dec 2021Series C$36.5M
- Mar 2020Series A$4.2M
- Aug 2019Series A$6.9M
#12
Deadpooled · New York City, New York · founded 2011$2.1Mraised▾
CORNOVUS Pharmaceuticals is a pharmaceutical company focused on developing cardioprotective agents for late-stage heart failure. The lead compound of the company, MRS2339 is a P2X4 receptor agonist. MRS2339 works by increasing myocardial cyclic guanosine monophosphate (GMP) which likely reflects a consequence of elevated nitric oxide levels(NOs). This molecule is in preclinical stage & the company claims that it has shown promising results.
- Jan 2024Conventional Debt—
- Jan 2024Seed$500K
- Dec 2020Grant (prize money)$1.4M
- Jul 2020Grant (prize money)$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.